Jun. 9 at 12:06 PM
Big Pharma is hunting for late-stage oncology. GSK buying Nuvalent TODAY for
$10.6B proves the premium for late-stage cancer assets.
$SLS is just 2 events away from the finish line. The 80th event triggers the unblinding for the Phase 3 REGAL trial this month or early July. 3x survival compared to control would be absolute magic for AML patients
A
$10B buyout equates to
$50.86 per share based on the current outstanding share count.
If Big Pharma gives
$10B for lung cancer drugs, a
$10B valuation for
$SLS's game-changing WT1 platform would completely rewrite the script, putting the share price well over
$50+ per share based on the current float. The countdown is officially on.
https://www.cnbc.com/2026/06/09/gsk-in-talks-to-acquire-nuvalent-for-more-than-9-billion.html
$LLY $MRK $PFE $ABBV